1. Home
  2. ARAI vs TCRX Comparison

ARAI vs TCRX Comparison

Compare ARAI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ARAI

Arrive AI Inc.

N/A

Current Price

$1.03

Market Cap

63.6M

Sector

Finance

ML Signal

N/A

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

N/A

Current Price

$1.18

Market Cap

63.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARAI
TCRX
Founded
2020
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.6M
63.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ARAI
TCRX
Price
$1.03
$1.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$12.00
$8.00
AVG Volume (30 Days)
289.2K
465.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.28
EPS
N/A
N/A
Revenue
N/A
$10,325,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$900.00
$69.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
266.65
52 Week Low
$0.96
$0.88
52 Week High
$15.50
$2.57

Technical Indicators

Market Signals
Indicator
ARAI
TCRX
Relative Strength Index (RSI) 29.09 61.50
Support Level N/A $1.16
Resistance Level $3.37 $1.23
Average True Range (ATR) 0.08 0.08
MACD 0.05 0.02
Stochastic Oscillator 33.33 71.80

Price Performance

Historical Comparison
ARAI
TCRX

About ARAI Arrive AI Inc.

Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advanced chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: